REG - Ergomed plc - Result of AGM

ErgomedAnnouncement

18/06/2019 15:00

RNS Number : 6573C
Ergomed plc
18 June 2019
 


PRESS RELEASE
FOR IMMEDIATE RELEASE
 
 
Results of 2019 Annual General Meeting
 
Guildford, UK - 18 June 2019: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a company focused on providing specialised services to the pharmaceutical industry, announces the results of voting on the resolutions put to shareholders at its Annual General Meeting held earlier today.  Resolutions 1 to 6 were duly passed, whilst Resolutions 7 and 8 were not passed.
 
Resolutions 1 to 5 were passed on a show of hands.  Details of proxy results were as follows:
 



Resolution number


Votes for


Votes against


Abstentions




1


20,232,290


77,125


8,649




2


20,160,715


156,099


1,250




3


16,997,564


Nil


3,320,500




4


20,316,814


Nil


1,250




5


20,302,774


14,040


1,250



 
Details of voting results for Resolutions 6, 7 and 8 (including proxies) were as follows:
 



Resolution number


Votes for


Votes against


Abstentions




6


27,839,992


10,681,500


1,250




7


27,683,893


10,837,599


1,250




8


27,610,768


10,910,724


1,250



 
The full text of all resolutions can be found in the Notice of Annual General Meeting on the Company's website www.ergomedplc.com
 
ENDS
 
 
 
 
 
Enquiries:
 



Ergomed plc


 Tel: +44 (0) 1483 402 975




Miroslav Reljanović (Executive Chairman)




























Numis Securities Limited


Tel: +44 (0) 20 7260 1000




Freddie Barnfield / Huw Jeremy (Nominated Adviser)








James Black (Broker)


















Consilium Strategic Communications - for UK enquiries


Tel: +44 (0) 20 3709 5700




Chris Gardner / Mary-Jane Elliott


ergomed@consilium-comms.com




Matthew Neal / Olivia Manser


















MC Services - for Continental European enquiries


Tel: +49 211 5292 5222




Anne Hennecke







 
 
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services business includes an industry leading suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, and a full range of high-quality contract research and trial management services under the Ergomed brand (CRO), and an internationally recognised specialist expertise in orphan drug development, under PSR. For further information, visit: http://ergomedplc.com.
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RAGLLFEVRTITLIA